Unfortunately, only a small percentage of CRC patients are sensitive to anti-EGFR therapy due to primary or innate resistance; and even those that initially respond, eventually acquire resistance and relapse under this therapy (secondary resistance). Here, EGFR is linked to colorectal carcinoma.